walgreens hero

Walgreens' specialty pharmacy to distribute Verrica's Ycanth

Ycanth is the first FDA-approved therapy for the treatment of molluscum contagiosum.

Verrica Pharmaceuticals has entered into an agreement with Walgreens to distribute Ycanth through its specialty pharmacy. Walgreens joins Verrica’s existing specialty pharmacy, Nufactor, who continues to be instrumental in helping the company build awareness of Ycanth therapy among high volume dermatology and pediatric medical practices. 

“We are excited to enter into this agreement with Walgreens to help bring the first FDA-approved therapy for the treatment of molluscum contagiosum, Ycanth, to the millions of adults and children who contract this viral skin disease each year,” said Ted White, president and CEO of Verrica Pharmaceuticals. 

[Read more: AllianceRx Walgreens Pharmacy makes new name official]

White added, “Walgreens and Verrica mutually recognize the need to address this significant unmet medical need in dermatology, and we look forward to working together to provide greater access to Ycanth for patients in need. We will also continue to work closely with Nufactor, our other specialty pharmacy, who continues to be an extraordinary partner.”   

This ad will auto-close in 10 seconds